Search

Your search keyword '"Tarr T"' showing total 192 results
Start Over Author "Tarr T"
192 results on '"Tarr T"'

2. Résultats de phase 2 d’efficacité et de tolérance jusqu’à 52 semaines du ianalumab, anti-BAFF récepteur (BAFF-R), chez les patients atteints de lupus érythémateux systémique (LES)

Author

Lazaro, E., primary, Agmon-Levin, N., additional, Ignatenko, S., additional, Gordienko, A., additional, Cortes-Hernandez, J., additional, Narongroeknawin, P., additional, Romanowska-Prochnicka, K., additional, Shen, N., additional, Ciferska, H., additional, Kodera, M., additional, Wei, C.C., additional, Leszczynski, P., additional, Lan, J.L., additional, Mysler, E., additional, Wojciechowski, R., additional, Tarr, T., additional, Vishneva, E., additional, Chen, Y.H., additional, Kaneko, Y., additional, Finzel, S., additional, Hoi, A., additional, Okada, M., additional, Koolvisoot, A., additional, Lee, S.S., additional, Dai, L., additional, Kaneko, H., additional, Rojkovich, B., additional, Sun, L., additional, Zotkin, E., additional, Magallares, B.P., additional, Sengupta, T., additional, Sips, C., additional, Oliver, S., additional, Avrameas, A., additional, and Lau, C., additional

Published
2024
Full Text
View/download PDF

4. POS0120 SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED MONTHLY OVER 28 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Author

Cortés-Hernández, J., primary, Ignatenko, S., additional, Gordienko, A., additional, Agmon-Levin, N., additional, Narongroeknawin, P., additional, Romanowska -Prochnicka, K., additional, Shen, N., additional, Ciferská, H., additional, Kodera, M., additional, Wei, J. C. C., additional, Leszczynski, P., additional, Lan, J. L., additional, Wojciechowski, R., additional, Tarr, T., additional, Vishneva, E., additional, Chen, Y. H., additional, Kaneko, Y., additional, Finzel, S., additional, Hoi, A., additional, Okada, M., additional, Koolvisoot, A., additional, Lee, S. S., additional, Dai, L., additional, Kaneko, H., additional, Rojkovich, B., additional, Sun, L., additional, Zotkin, E., additional, Magallares, B., additional, Sengupta, T., additional, Sips, C., additional, and Oliver, S., additional

Published
2023
Full Text
View/download PDF

7. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients

Author

Cervera, R, Serrano, R, Pons-Estel, G J, Ceberio-Hualde, L, Shoenfeld, Y, de Ramón, E, Buonaiuto, V, Jacobsen, S, Zeher, M M, Tarr, T, Tincani, A, Taglietti, M, Theodossiades, G, Nomikou, E, Galeazzi, M, Bellisai, F, Meroni, P L, Derksen, R H W M, de Groot, P G D, Baleva, M, Mosca, M, Bombardieri, S, Houssiau, F, Gris, J-C, Quéré, I, Hachulla, E, Vasconcelos, C, Fernández-Nebro, A, Haro, M, Amoura, Z, Miyara, M, Tektonidou, M, Espinosa, G, Bertolaccini, M L, and Khamashta, M A

Published
2015
Full Text
View/download PDF

8. SARS-CoV-2 infection in patients with primary Sjögren syndrome: Characterization and outcomes of 51 patients

Author

Medicina i Cirurgia, Universitat Rovira i Virgili, Brito-Zerón P; Brito-Zerón P; Melchor S; Seror R; Seror R; Priori R; Priori R; Solans R; Solans R; Kostov B; Kostov B; Baldini C; Carubbi F; Carubbi F; Callejas JL; Guisado-Vasco P; Hernández-Molina G; Hernández-Molina G; Pasoto SG; Pasoto SG; Valim V; Valim V; Sisó-Almirall A; Sisó-Almirall A; Mariette X; Carreira P; Ramos-Casals M; Brito-Zerón P; Morcillo C; Flores-Chávez A; Acar-Denizli N; Horvath IF; Szanto A; Tarr T; Mandl T; Olsson P; Li X; Xu B; Baldini C; Bombardieri S; Gottenberg JE; Gandolfo S; De Vita S; Giardina F; Sánchez-Guerrero J; Kruize AA; Hinrichs A; Isenberg D; Rischmueller M; Downie-Doyle S; Kwok SK; Park SH; Nordmark G; Suzuki Y; Kawano M; Giacomelli R; Devauchelle-Pensec V; Saraux A; Hofauer B; Knopf A; Bootsma H; Vissink A; Morel J; Vollenveider C; Atzeni F; Retamozo S; Moça Trevisano V; Armagan B; Kilic L; Kalyoncu U; Consani-Fernández S; Callejas JL; López-Dupla M; Pérez-Alvarez R; Akasbi M; Sánchez I, Medicina i Cirurgia, Universitat Rovira i Virgili, and Brito-Zerón P; Brito-Zerón P; Melchor S; Seror R; Seror R; Priori R; Priori R; Solans R; Solans R; Kostov B; Kostov B; Baldini C; Carubbi F; Carubbi F; Callejas JL; Guisado-Vasco P; Hernández-Molina G; Hernández-Molina G; Pasoto SG; Pasoto SG; Valim V; Valim V; Sisó-Almirall A; Sisó-Almirall A; Mariette X; Carreira P; Ramos-Casals M; Brito-Zerón P; Morcillo C; Flores-Chávez A; Acar-Denizli N; Horvath IF; Szanto A; Tarr T; Mandl T; Olsson P; Li X; Xu B; Baldini C; Bombardieri S; Gottenberg JE; Gandolfo S; De Vita S; Giardina F; Sánchez-Guerrero J; Kruize AA; Hinrichs A; Isenberg D; Rischmueller M; Downie-Doyle S; Kwok SK; Park SH; Nordmark G; Suzuki Y; Kawano M; Giacomelli R; Devauchelle-Pensec V; Saraux A; Hofauer B; Knopf A; Bootsma H; Vissink A; Morel J; Vollenveider C; Atzeni F; Retamozo S; Moça Trevisano V; Armagan B; Kilic L; Kalyoncu U; Consani-Fernández S; Callejas JL; López-Dupla M; Pérez-Alvarez R; Akasbi M; Sánchez I

Abstract

Objective: To analyse the prognosis and outcomes of SARS-CoV-2 infection in patients with primary SS. Methods: We searched for patients with primary SS presenting with SARS-CoV-2 infection (defined following and according to the European Centre for Disease Prevention and Control guidelines) among those included in the Big Data Sjögren Registry, an international, multicentre registry of patients diagnosed according to the 2002/2016 classification criteria. Results: A total of 51 patients were included in the study (46 women, mean age at diagnosis of infection of 60 years). According to the number of patients with primary SS evaluated in the Registry (n = 8211), the estimated frequency of SARS-CoV-2 infection was 0.62% (95% CI 0.44, 0.80). All but two presented with symptoms suggestive of COVID-19, including fever (82%), cough (57%), dyspnoea (39%), fatigue/myalgias (27%) and diarrhoea (24%), and the most frequent abnormalities included raised lactate dehydrogenase (LDH) (88%), CRP (81%) and D-dimer (82%) values, and lymphopenia (70%). Infection was managed at home in 26 (51%) cases and 25 (49%) required hospitalization (five required admission to ICU, four died). Compared with patients managed at home, those requiring hospitalization had higher odds of having lymphopenia as laboratory abnormality (adjusted OR 21.22, 95% CI 2.39, 524.09). Patients with comorbidities had an older age (adjusted OR 1.05, 95% CI 1.00, 1.11) and showed a risk for hospital admission six times higher than those without (adjusted OR 6.01, 95% CI 1.72, 23.51) in the multivariate analysis. Conclusion: Baseline comorbidities were a key risk factor for a more complicated COVID-19 in patients with primary SS, with higher rates of hospitalization and poor outcomes in comparison with patients without co

Published
2021

9. SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients

Author

Brito-Zerón, Pilar, Melchor, Sheila, Seror, Raphaèle, Priori, Roberta, Solans, Roser, Kostov, Belchin, Baldini, Chiara, Carubbi, Francesco, Callejas, Jose Luis, Guisado-Vasco, Pablo, Hernández-Molina, Gabriela, Pasoto, Sandra G, Valim, Valeria, Sisó-Almirall, Antoni, Mariette, Xavier, Carreira, Patricia, Ramos-Casals, Manuel, Brito-Zerón, P, Morcillo, C, Flores-Chávez, A, Ramos-Casals, M, Acar-Denizli, N, Horvath, I F, Szanto, A, Tarr, T, Seror, R, Mariette, X, Mandl, T, Olsson, P, Li, X, Xu, B, Baldini, C, Bombardieri, S, Gottenberg, J E, Gandolfo, S, De Vita, S, Priori, R, Giardina, F, Hernandez-Molina, G, Sánchez-Guerrero, J, Kruize, A A, Hinrichs, A, Valim, V, Isenberg, D, Solans, R, Rischmueller, M, Downie-Doyle, S, Kwok, S-K, Park, S-H, Nordmark, G, Suzuki, Y, Kawano, M, Giacomelli, R, Devauchelle-Pensec, V, Saraux, A, Hofauer, B, Knopf, A, Bootsma, H, Vissink, A, Morel, J, Vollenveider, C, Atzeni, F, Retamozo, S, Moça Trevisano, V, Armagan, B, Kilic, L, Kalyoncu, U, Pasoto, S G, Kostov, B, Sisó-Almirall, A, Consani-Fernández, S, Carubbi, F, Callejas, J L, López-Dupla, M, Pérez-Alvarez, R, Akasbi, M, Guisado-Vasco, P, Sánchez, I, Hospital Universitario 12 de Octubre [Madrid], EULAR standing committee of People with Arthritis/Rheumatism in Europe (PARE), H. CIMA-Sanitas, Barcelona, CELLEX-IDIBAPS Department of Autoimmune Diseases, Barcelona, Instituto Mexicano del Seguro Social [Mexico City, Mexico] (IMSS), Universidad de Colima [Mexico], Hospital Clinic [Barcelona, Spain], İstanbul Üniversitesi, İstanbul, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary, MTA-Debreceni Egyetem, Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Center for Immunology of Viral Infections and Autoimmune Diseases, Le Kremlin Bicêtre, Skåne University Hospital [Malmö, Suède], Stockholm University, Wuhan University [China], Pisa University Hospital, Nuclear Medicine Unit, Humanitas Gavazzeni, Bergamo, Italy, University Hospitals, Strasbourg, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome] (UNIROMA), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán - National Institute of Medical Science and Nutrition Salvador Zubiran [Mexico], Federal University of Espírito Santo, University Hospital Vall d’Hebròn [Barcelona, Spain], Lymphocytes B, Autoimmunité et Immunothérapies (LBAI), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-LabEX IGO Immunothérapie Grand Ouest, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut d'Investigaciones Biomèdiques August Pi i Sunye (IDIBAPS), Università degli studi di Palermo - University of Palermo, Hospitales Universitarios de Granada/Universidad de Granada, Hospital Universitario Quironsalud, Università degli Studi di Roma 'La Sapienza' = Sapienza University [Rome], Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Rheumatology Unit, Department of Internal Medicine, University of Palermo, Palermo, Italy, and Michel, Geneviève

Subjects
Male, medicine.medical_specialty, Multivariate analysis, [SDV.IMM] Life Sciences [q-bio]/Immunology, Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Comorbidity, Laboratory abnormality, comorbidities, outcomes, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Risk Factors, Internal medicine, medicine, Humans, In patient, Pharmacology (medical), 030212 general & internal medicine, Registries, Risk factor, Primary Sjögren Syndrome, AcademicSubjects/MED00360, ComputingMilieux_MISCELLANEOUS, 030203 arthritis & rheumatology, business.industry, SARS-CoV-2, COVID-19, Primary SS, SARS-Cov-2, Middle Aged, medicine.disease, 3. Good health, Hospitalization, Sjogren's Syndrome, [SDV.IMM]Life Sciences [q-bio]/Immunology, Original Article, Female, business
Abstract

Objective To analyse the prognosis and outcomes of SARS-CoV-2 infection in patients with primary SS. Methods We searched for patients with primary SS presenting with SARS-CoV-2 infection (defined following and according to the European Centre for Disease Prevention and Control guidelines) among those included in the Big Data Sjögren Registry, an international, multicentre registry of patients diagnosed according to the 2002/2016 classification criteria. Results A total of 51 patients were included in the study (46 women, mean age at diagnosis of infection of 60 years). According to the number of patients with primary SS evaluated in the Registry (n = 8211), the estimated frequency of SARS-CoV-2 infection was 0.62% (95% CI 0.44, 0.80). All but two presented with symptoms suggestive of COVID-19, including fever (82%), cough (57%), dyspnoea (39%), fatigue/myalgias (27%) and diarrhoea (24%), and the most frequent abnormalities included raised lactate dehydrogenase (LDH) (88%), CRP (81%) and D-dimer (82%) values, and lymphopenia (70%). Infection was managed at home in 26 (51%) cases and 25 (49%) required hospitalization (five required admission to ICU, four died). Compared with patients managed at home, those requiring hospitalization had higher odds of having lymphopenia as laboratory abnormality (adjusted OR 21.22, 95% CI 2.39, 524.09). Patients with comorbidities had an older age (adjusted OR 1.05, 95% CI 1.00, 1.11) and showed a risk for hospital admission six times higher than those without (adjusted OR 6.01, 95% CI 1.72, 23.51) in the multivariate analysis. Conclusion Baseline comorbidities were a key risk factor for a more complicated COVID-19 in patients with primary SS, with higher rates of hospitalization and poor outcomes in comparison with patients without comorbidities.

Published
2020

19. SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED MONTHLY OVER 28 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).

Author

Cortés-Hernández, J., Ignatenko, S., Gordienko, A., Agmon-Levin, N., Narongroeknawin, P., Romanowska-Prochnicka, K., Shen, N., Ciferská, H., Kodera, M., Wei, J. C. C., Leszczynski, P., Lan, J. L., Wojciechowski, R., Tarr, T., Vishneva, E., Chen, Y. H., Kaneko, Y., Finzel, S., Hoi, A., and Okada, M.

Published
2023
Full Text
View/download PDF

21. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients

Author

Cervera, R. Serrano, R. Pons-Estel, G. J. Ceberio-Hualde, L. and Shoenfeld, Y. de Ramon, E. Buonaiuto, V. Jacobsen, S. and Zeher, M. M. Tarr, T. Tincani, A. Taglietti, M. and Theodossiades, G. Nomikou, E. Galeazzi, M. Bellisai, F. and Meroni, P. L. Derksen, R. H. W. M. de Groot, P. G. D. and Baleva, M. Mosca, M. Bombardieri, S. Houssiau, F. Gris, J-C Quere, I. Hachulla, E. Vasconcelos, C. and Fernandez-Nebro, A. Haro, M. Amoura, Z. Miyara, M. and Tektonidou, M. Espinosa, G. Bertolaccini, M. L. Khamashta, M. A. Euro-Phospholipid Project Grp

Abstract

Objectives To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid syndrome (APS) during a 10-year-follow-up period and to compare the frequency of early manifestations with those that appeared later. Methods In 1999, we started an observational study of 1000 APS patients from 13 European countries. All had medical histories documented when entered into the study and were followed prospectively during the ensuing 10years. Results 53.1% of the patients had primary APS, 36.2% had APS associated with systemic lupus erythematosus and 10.7% APS associated with other diseases. Thrombotic events appeared in 166 (16.6%) patients during the first 5-year period and in 115 (14.4%) during the second 5-year period. The most common events were strokes, transient ischaemic attacks, deep vein thromboses and pulmonary embolism. 127 (15.5%) women became pregnant (188 pregnancies) and 72.9% of pregnancies succeeded in having one or more live births. The most common obstetric complication was early pregnancy loss (16.5% of the pregnancies). Intrauterine growth restriction (26.3% of the total live births) and prematurity (48.2%) were the most frequent fetal morbidities. 93 (9.3%) patients died and the most frequent causes of death were severe thrombosis (36.5%) and infections (26.9%). Nine (0.9%) cases of catastrophic APS occurred and 5 (55.6%) of them died. The survival probability at 10years was 90.7%. Conclusions Patients with APS still develop significant morbidity and mortality despite current treatment. It is imperative to increase the efforts in determining optimal prognostic markers and therapeutic measures to prevent these complications.

Published
2015

23. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period : A multicentre prospective study of 1000 patients

Author

Cervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., De Ramón, E., Buonaiuto, V., Jacobsen, S., Zeher, M. M., Tarr, T., Tincani, A., Taglietti, M., Theodossiades, G., Nomikou, E., Galeazzi, M., Bellisai, F., Meroni, P. L., Derksen, R. H W M, De Groot, P. G D, Baleva, M., Mosca, S., Bombardieri, M., Houssiau, F., Gris, J. C., Quéré, I., Hachulla, E., Vasconcelos, C., Fernández-Nebro, A., Haro, M., Amoura, Z., Miyara, M., Tektonidou, M., Espinosa, G., Bertolaccini, M. L., Khamashta, M. A., Cervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., De Ramón, E., Buonaiuto, V., Jacobsen, S., Zeher, M. M., Tarr, T., Tincani, A., Taglietti, M., Theodossiades, G., Nomikou, E., Galeazzi, M., Bellisai, F., Meroni, P. L., Derksen, R. H W M, De Groot, P. G D, Baleva, M., Mosca, S., Bombardieri, M., Houssiau, F., Gris, J. C., Quéré, I., Hachulla, E., Vasconcelos, C., Fernández-Nebro, A., Haro, M., Amoura, Z., Miyara, M., Tektonidou, M., Espinosa, G., Bertolaccini, M. L., and Khamashta, M. A.

Published
2015

24. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients

Author

UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Cervera, R, Serrano, R, Pons-Estel, G J, Ceberio-Hualde, L, Shoenfeld, Y, de Ramón, E, Buonaiuto, V, Jacobsen, S, Zeher, M M, Tarr, T, Tincani, A, Taglietti, M, Theodossiades, G, Nomikou, E, Galeazzi, M, Bellisai, F, Meroni, P L, Derksen, R H W M, de Groot, P G D, Baleva, M, Mosca, M, Bombardieri, S, Houssiau, Frédéric, Gris, J-C, Quéré, I, Hachulla, E, Vasconcelos, C, Fernández-Nebro, A, Haro, M, Amoura, Z, Miyara, M, Tektonidou, M, Espinosa, G, Bertolaccini, M L, Khamashta, M A, Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies), UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Cervera, R, Serrano, R, Pons-Estel, G J, Ceberio-Hualde, L, Shoenfeld, Y, de Ramón, E, Buonaiuto, V, Jacobsen, S, Zeher, M M, Tarr, T, Tincani, A, Taglietti, M, Theodossiades, G, Nomikou, E, Galeazzi, M, Bellisai, F, Meroni, P L, Derksen, R H W M, de Groot, P G D, Baleva, M, Mosca, M, Bombardieri, S, Houssiau, Frédéric, Gris, J-C, Quéré, I, Hachulla, E, Vasconcelos, C, Fernández-Nebro, A, Haro, M, Amoura, Z, Miyara, M, Tektonidou, M, Espinosa, G, Bertolaccini, M L, Khamashta, M A, and Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies)

Abstract

OBJECTIVES: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid syndrome (APS) during a 10-year-follow-up period and to compare the frequency of early manifestations with those that appeared later. METHODS: In 1999, we started an observational study of 1000 APS patients from 13 European countries. All had medical histories documented when entered into the study and were followed prospectively during the ensuing 10 years. RESULTS: 53.1% of the patients had primary APS, 36.2% had APS associated with systemic lupus erythematosus and 10.7% APS associated with other diseases. Thrombotic events appeared in 166 (16.6%) patients during the first 5-year period and in 115 (14.4%) during the second 5-year period. The most common events were strokes, transient ischaemic attacks, deep vein thromboses and pulmonary embolism. 127 (15.5%) women became pregnant (188 pregnancies) and 72.9% of pregnancies succeeded in having one or more live births. The most common obstetric complication was early pregnancy loss (16.5% of the pregnancies). Intrauterine growth restriction (26.3% of the total live births) and prematurity (48.2%) were the most frequent fetal morbidities. 93 (9.3%) patients died and the most frequent causes of death were severe thrombosis (36.5%) and infections (26.9%). Nine (0.9%) cases of catastrophic APS occurred and 5 (55.6%) of them died. The survival probability at 10 years was 90.7%. CONCLUSIONS: Patients with APS still develop significant morbidity and mortality despite current treatment. It is imperative to increase the efforts in determining optimal prognostic markers and therapeutic measures to prevent these complications.

Published
2015

25. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients

Author

MS Reumatologie/Immunologie/Infectie, LKCH Overige medewerkers O&O, Cervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., De Ramón, E., Buonaiuto, V., Jacobsen, S., Zeher, M. M., Tarr, T., Tincani, A., Taglietti, M., Theodossiades, G., Nomikou, E., Galeazzi, M., Bellisai, F., Meroni, P. L., Derksen, R. H W M, De Groot, P. G D, Baleva, M., Mosca, S., Bombardieri, M., Houssiau, F., Gris, J. C., Quéré, I., Hachulla, E., Vasconcelos, C., Fernández-Nebro, A., Haro, M., Amoura, Z., Miyara, M., Tektonidou, M., Espinosa, G., Bertolaccini, M. L., Khamashta, M. A., MS Reumatologie/Immunologie/Infectie, LKCH Overige medewerkers O&O, Cervera, R., Serrano, R., Pons-Estel, G. J., Ceberio-Hualde, L., Shoenfeld, Y., De Ramón, E., Buonaiuto, V., Jacobsen, S., Zeher, M. M., Tarr, T., Tincani, A., Taglietti, M., Theodossiades, G., Nomikou, E., Galeazzi, M., Bellisai, F., Meroni, P. L., Derksen, R. H W M, De Groot, P. G D, Baleva, M., Mosca, S., Bombardieri, M., Houssiau, F., Gris, J. C., Quéré, I., Hachulla, E., Vasconcelos, C., Fernández-Nebro, A., Haro, M., Amoura, Z., Miyara, M., Tektonidou, M., Espinosa, G., Bertolaccini, M. L., and Khamashta, M. A.

Published
2015

26. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period:a multicentre prospective study of 1000 patients

Author

Cervera, R, Serrano, R, Pons-Estel, G J, Ceberio-Hualde, L, Shoenfeld, Y, de Ramón, E, Buonaiuto, V, Jacobsen, Søren, Zeher, M M, Tarr, T, Tincani, A, Taglietti, M, Theodossiades, G, Nomikou, E, Galeazzi, M, Bellisai, F, Meroni, P L, Derksen, R H W M, de Groot, P G D, Baleva, M, Mosca, M, Bombardieri, S, Houssiau, F, Gris, J-C, Quéré, I, Hachulla, E, Vasconcelos, C, Fernández-Nebro, A, Haro, M, Amoura, Z, Miyara, M, Tektonidou, M, Espinosa, G, Bertolaccini, M L, Khamashta, M A, Cervera, R, Serrano, R, Pons-Estel, G J, Ceberio-Hualde, L, Shoenfeld, Y, de Ramón, E, Buonaiuto, V, Jacobsen, Søren, Zeher, M M, Tarr, T, Tincani, A, Taglietti, M, Theodossiades, G, Nomikou, E, Galeazzi, M, Bellisai, F, Meroni, P L, Derksen, R H W M, de Groot, P G D, Baleva, M, Mosca, M, Bombardieri, S, Houssiau, F, Gris, J-C, Quéré, I, Hachulla, E, Vasconcelos, C, Fernández-Nebro, A, Haro, M, Amoura, Z, Miyara, M, Tektonidou, M, Espinosa, G, Bertolaccini, M L, and Khamashta, M A

Abstract

OBJECTIVES: To assess the prevalence of the main causes of morbi-mortality in the antiphospholipid syndrome (APS) during a 10-year-follow-up period and to compare the frequency of early manifestations with those that appeared later.METHODS: In 1999, we started an observational study of 1000 APS patients from 13 European countries. All had medical histories documented when entered into the study and were followed prospectively during the ensuing 10 years.RESULTS: 53.1% of the patients had primary APS, 36.2% had APS associated with systemic lupus erythematosus and 10.7% APS associated with other diseases. Thrombotic events appeared in 166 (16.6%) patients during the first 5-year period and in 115 (14.4%) during the second 5-year period. The most common events were strokes, transient ischaemic attacks, deep vein thromboses and pulmonary embolism. 127 (15.5%) women became pregnant (188 pregnancies) and 72.9% of pregnancies succeeded in having one or more live births. The most common obstetric complication was early pregnancy loss (16.5% of the pregnancies). Intrauterine growth restriction (26.3% of the total live births) and prematurity (48.2%) were the most frequent fetal morbidities. 93 (9.3%) patients died and the most frequent causes of death were severe thrombosis (36.5%) and infections (26.9%). Nine (0.9%) cases of catastrophic APS occurred and 5 (55.6%) of them died. The survival probability at 10 years was 90.7%.CONCLUSIONS: Patients with APS still develop significant morbidity and mortality despite current treatment. It is imperative to increase the efforts in determining optimal prognostic markers and therapeutic measures to prevent these complications.

Published
2015

31. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients

Author

Cervera, R, primary, Serrano, R, additional, Pons-Estel, G J, additional, Ceberio-Hualde, L, additional, Shoenfeld, Y, additional, de Ramón, E, additional, Buonaiuto, V, additional, Jacobsen, S, additional, Zeher, M M, additional, Tarr, T, additional, Tincani, A, additional, Taglietti, M, additional, Theodossiades, G, additional, Nomikou, E, additional, Galeazzi, M, additional, Bellisai, F, additional, Meroni, P L, additional, Derksen, R H W M, additional, de Groot, P G D, additional, Baleva, M, additional, Mosca, M, additional, Bombardieri, S, additional, Houssiau, F, additional, Gris, J-C, additional, Quéré, I, additional, Hachulla, E, additional, Vasconcelos, C, additional, Fernández-Nebro, A, additional, Haro, M, additional, Amoura, Z, additional, Miyara, M, additional, Tektonidou, M, additional, Espinosa, G, additional, Bertolaccini, M L, additional, and Khamashta, M A, additional

Published
2014
Full Text
View/download PDF

37. Age related clinical presentation and laboratory parameters in juvenile SLE: a Hungarian multicenter study

Author

Derfalvi, B, primary, Malik, A, additional, Kreko, M, additional, Pasti, K, additional, Tarr, T, additional, Marton, G, additional, Gyorke, Zs, additional, Mosdosi, B, additional, Nyul, Z, additional, Noll, J, additional, Csurke, I, additional, Harangi, F, additional, Balogh, Zs, additional, Orban, I, additional, Sevcic, K, additional, Kiss, E, additional, Kaposzta, R, additional, Szucs, B, additional, Turi, S, additional, Sallay, P, additional, Reusz, Gy, additional, Tulassay, T, additional, and Szabo, AJ, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results